Evidence map›Paper›PMID 16188978›Full record

ArticleJournal of virology2005

Activation of the Jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells.

Kazuo Nishigaki, Charlotte Hanson, Delores Thompson, Takashi Yugawa, Sandra Ruscetti

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Inhibitors of c-Jun N-terminal kinases: JuNK no more?Biochimica et biophysica acta · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kazuo NishigakiLaboratory of Cancer Prevention, National Cancer Institute--Frederick, MD 21702-1201, USA.
Charlotte Hanson
Delores Thompson
Takashi Yugawa
Sandra Ruscetti
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · US

Funding

Molecular Basis for the Pathogenesis of Murine RetrovirusesZIABC005657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUSCETTI, SANDRA K · 2009 to 2013
$5.2M
MOLECULAR BASIS FOR THE PATHOGENESIS OF MURINE RETROVIRUSESZ01BC005657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RUSCETTI, SANDRA K · 1996 to 2008
$2.7M
6 · The paper itself

Abstract

Members of the mitogen-activated protein kinase (MAPK) family, including Jun amino-terminal kinase (JNK) and extracellular signal-related kinase (ERK), play an important role in the proliferation of erythroid cells in response to erythropoietin (Epo). Erythroid cells infected with the Friend spleen focus-forming virus (SFFV) proliferate in the absence of Epo and show constitutive activation of Epo signal transduction pathways. We previously demonstrated that the ERK pathway was constitutively activated in Friend SFFV-infected erythroid cells, and in this study JNK is also shown to be constitutively activated. Pharmacological inhibitors of both the ERK and JNK pathways stopped the proliferation of primary erythroleukemic cells from Friend SFFV-infected mice, with little induction of apoptosis, and furthermore blocked their ability to form Epo-independent colonies. However, only the JNK inhibitor blocked the proliferation of erythroleukemia cell lines derived from these mice. The JNK inhibitor caused significant apoptosis in these cell lines as well as an increase in the fraction of cells in G(2)/M and undergoing endoreduplication. In contrast, the growth of erythroleukemia cell lines derived from Friend murine leukemia virus (MuLV)-infected mice was inhibited by both the MEK and JNK inhibitors. JNK is important for AP1 activity, and we found that JNK inhibitor treatment reduced AP1 DNA-binding activity in primary erythroleukemic splenocytes from Friend SFFV-infected mice and in erythroleukemia cell lines from Friend MuLV-infected mice but did not alter AP1 DNA binding in erythroleukemia cell lines from Friend SFFV-infected mice. These data suggest that JNK plays an important role in cell proliferation and/or the survival of erythroleukemia cells.

Indexed as

Signal TransductionAnimalsAnthracenesApoptosisCalcium-Calmodulin-Dependent Protein KinasesCell Line, TransformedCell ProliferationCells, CulturedCell Transformation, ViralErythropoietinExtracellular Signal-Regulated MAP KinasesFlavonoidsJNK Mitogen-Activated Protein KinasesLeukemia, ExperimentalMAP Kinase Kinase KinasesMice2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneAnthracenesCalcium-Calmodulin-Dependent Protein KinasesErythropoietinExtracellular Signal-Regulated MAP KinasesFlavonoidsJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase KinasespyrazolanthroneTranscription Factor AP-1

Identifiers

PMID16188978
PMCPMC1235824
OpenAlexW1997624076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.